CEO Dov Tamarkin: We believe that our products will revolutionize the results and ease-of-use of dermatology products.
Sources inform ''Globes'' that Foamix Ltd. and Moshe (Mori) Arkin's Arkin Holdings Ltd. have signed an agreement to jointly develop a foam for the treatment of acne.
Foamix develops foam and gel-based versions of current and new dermatological and gynecological drugs. The company is developing foams to replace current gels and creams, in order to improve absorbency of the drugs through the skin and improve their efficacy. The company has several cooperation agreements, including with India's Dr Reddy's Laboratories Ltd. (NYSE: RDY; BSE: 500124), Germany's Bayer AG (DAX: BAYN), and Ferndale Laboratories Inc. and Warner Chilcott plc (Nasdaq: WRCX) of the US.
Arkin told "Globes", "We love collaborating with Foamix. The company has strong development capabilities and a focus on dermatology treatments, which is why we believe that it is an excellent partner to promote the current product."
Foamix CEO Dov Tamarkin said, "We believe that our products will revolutionize the results and ease-of-use of dermatology products."
Published by Globes [online], Israel business news - www.globes-online.com - on May 26, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011